Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Non-Current Assets for 4 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 19.02% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $75.2 million (down 47.59% YoY), while the FY2025 annual figure was $18.3 million, down 12.77% from the prior year.
• Non-Current Assets declined to $17.2 million in Q1 2026 per ARTV's latest filing, from $18.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $75.0 million in Q3 2024 and bottomed at $17.2 million in Q1 2026.
• Historically, Non-Current Assets has averaged $27.1 million across 4 years, with a median of $21.0 million in 2024.
• On a YoY basis, Non-Current Assets climbed as much as 12.77% in 2025 and fell as far as 74.23% in 2025.
• Artiva Biotherapeutics' Non-Current Assets stood at $25.3 million in 2023, then decreased by 17.17% to $21.0 million in 2024, then decreased by 12.77% to $18.3 million in 2025, then dropped by 5.8% to $17.2 million in 2026.
• Business Quant data shows ARTV's Non-Current Assets at $17.2 million in Q1 2026, $18.3 million in Q4 2025, and $19.3 million in Q3 2025.